Company intelligence / Profile preview

Cessation Therapeutics

Chapel Hill, North Carolina, United Statescessationtherapeutics.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Preliminary data from Phase 1a first-in-human study showed CSX-1004 is safe and well-tolerated under the conditions tested. The exposure data were predictive of efficacy for blocking fentanyl-induced respiratory depression. In non-human primates, CSX-1004 provided robust and durable protection from life-threatening respiratory depression caused by high doses of fentanyl for at least 3 weeks after a single administration.[3][7]

Therapeutic areas: PsychiatryNeurology
Modalities: Monoclonal antibodies (mAbs)Immunobiologics
Industry: Biotech

Drug pipeline

3 assets

CSX1004

2 more assets in the full pipeline.

Request access →

Partnerships

McLean Hospital (a member of Mass General Brigham)National Institute on Drug Abuse (NIDA)

Beyond the preview

Go deeper on Cessation Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cessation Therapeutics.

Explore the full profile